Abstract
This multicenter prospective study evaluates the efficacy and safety of bronchial arterial chemoembolization using CalliSpheres drug-eluting beads (DEB-BACE) for patients with refractory non-small-cell lung cancer (NSCLC). Results indicate that DEB-BACE is a highly effective salvage therapy, achieving a 95.35% disease control rate and significantly improving quality of life (QoL) with manageable side effects.
Introduction
Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancer diagnoses. Despite advancements in surgery, chemotherapy, and targeted therapies, many patients eventually reach a refractory stage where standard treatments fail. In these cases, palliative care becomes the primary focus to manage debilitating symptoms such as chronic cough, pain, and respiratory distress.
Traditional bronchial arterial chemoembolization (BACE), which utilizes iodized oil and chemotherapy, has long been a palliative option. However, it is often limited by incomplete embolization and high complication rates. This study investigates the use of CalliSpheres drug-eluting beads (DEB) as a superior alternative, designed to provide stable vascular occlusion while ensuring the sustained, localized release of chemotherapeutic agents.
Methods and Materials
The researchers conducted a multicenter prospective study involving 43 patients with refractory NSCLC who had failed previous lines of therapy. The core intervention was DEB-BACE using CalliSpheres (300–500 μm microspheres).
The DEB-BACE Procedure
The microspheres were loaded with 40–60 mg of epirubicin. The loading process involves the drug being absorbed by the beads, ensuring a concentrated delivery system that can be monitored visually during preparation.
Using the modified Seldinger technique, clinicians navigated a microcatheter into the specific bronchial arteries supplying the tumor. The drug-loaded beads were then slowly injected until blood flow reached "near-stasis." Tumor response was evaluated two months post-procedure via chest CT scans using the modified Response Evaluation Criteria in Solid Tumors (mRECIST).
Results
The clinical outcomes for the refractory patient cohort were remarkably positive, demonstrating both anatomical and symptomatic improvement.
Tumor Response and Survival
The study reported an Objective Response Rate (ORR) of 88.37% and a Disease Control Rate (DCR) of 95.35%. The median Overall Survival (OS) was 11.5 months, with survival rates at 6, 12, and 24 months reaching 86.0%, 41.9%, and 11.8%, respectively.
Symptom Relief and Quality of Life
Beyond tumor shrinkage, the treatment significantly alleviated clinical symptoms. Coughing and wheezing improved in 31 patients, and hemoptysis was controlled in all 12 patients who presented with it. Statistically significant improvements (P < 0.05) were observed in physical and emotional functioning, alongside marked reductions in fatigue, pain, and dyspnea.
Safety Profile
Safety is a critical concern in bronchial artery procedures due to the risk of ectopic embolism. This study reported zero serious adverse events, such as spinal cord injury or cerebral embolism. The most common side effects were mild (Grade 1) chest pain (30%) and Grade 1–2 fever (23%), which typically resolved within 3–5 days.
Discussion
The efficacy of DEB-BACE stems from its dual-action mechanism: physical embolization starves the tumor of nutrients, while the beads act as a reservoir for the slow release of chemotherapy. This increases the drug's "dwell time" within the tumor and minimizes systemic toxicity. The 300–500 μm bead size appears to be an optimal "sweet spot," providing effective occlusion without the risks associated with smaller particles entering systemic circulation.
Limitations
While promising, the study is limited by its small sample size (n=43) and the lack of a randomized control group. Future research should focus on large-scale, multicenter randomized controlled trials (RCTs) to compare DEB-BACE directly against traditional BACE and other palliative interventions.
Conclusion
DEB-BACE using CalliSpheres is an effective and safe salvage therapy for refractory NSCLC. By providing high disease control rates and significantly enhancing patient quality of life, it represents a valuable addition to the clinical toolkit for advanced lung cancer management.
Summary updated